Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYBB | P04839 | 2/20 | 0.70 |
| ▸ | ROCK1 | Q13464 | 13/20 | 0.39 |
| ▸ | CDC42BPB | Q9Y5S2 | 13/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14158657 | 0.87 | CYBB (0.58) | CYBBNOTUMMAP4K1NLRP3 | |
| SCHEMBL14158539 | 0.84 | CYBB (0.83) | CYBBNOTUMNLRP3 | |
| SCHEMBL14158858 | 0.84 | CYBB (0.64) | CYBBNOTUMNLRP3 | |
| SCHEMBL14158596 | 0.82 | CYBB (1.00) | CYBBNOTUMNLRP3 | |
| SCHEMBL14158705 | 0.82 | CYBB (0.69) | CYBBNOTUMNLRP3 | |
| SCHEMBL14158872 | 0.82 | CYBB (0.78) | CYBBNOTUMNLRP3 | |
| SCHEMBL14242798 | 0.80 | CYBB (0.75) | CYBBNLRP3 | |
| SCHEMBL14158922 | 0.79 | CYBB (0.72) | CYBBNOTUMNLRP3 | |
| SCHEMBL14158643 | 0.79 | ROCK1 (0.46) | CYBBROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL14243194 | 0.79 | CYBB (0.74) | CYBBNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-8877742-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED (GB) | 2014-11-04 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140155375-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Interllectual Property Limited (GB) | 2014-06-05 | — | — | US | disclosed |
| EP-2717694-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012170752-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170752-A1 | NOVEL COMPOUNDS | GLAXO WELLCOME MANUFACTURING PTE LTD (SG) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155375-A1 | NOVEL COMPOUNDS | CYBB, NOX1, NOX4 | CYBB 1/4885ROCK1 852/4885CDC42BPB 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.